SEC Form 4 · accession 0001209191-18-038159
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Nelsen
Director · 10% Owner
Period of report
Jun 13, 2018
Accepted (ET)
Jun 15, 2018 · 6:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $18.92 | Jun 13, 2018 | A | 27,830 | A | — | Jun 12, 2028 | Common Stock | 27,830 | 27,830 | D |
Explanation of responses
- F1100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date.